2,775
Views
8
CrossRef citations to date
0
Altmetric
Renal Disease

Chronic kidney disease in Spain: analysis of patient characteristics, incidence and direct medical costs (2011–2017)

&
Pages 1623-1629 | Received 21 May 2020, Accepted 12 Sep 2020, Published online: 27 Oct 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

José Ramón González-Juanatey, Álvaro González-Franco, Patricia de Sequera, Marta Valls, Antonio Ramirez de Arellano, Elisenda Pomares & Diana Nieves. (2022) A cost-effectiveness analysis of patiromer for the treatment of hyperkalemia in chronic kidney disease patients with and without heart failure in Spain. Journal of Medical Economics 25:1, pages 640-649.
Read now

Articles from other publishers (7)

Jose R. López‐Mínguez, A. L. Martín de Francisco, M. J. Soler, Felipe Hernández, Raul Moreno, Eduardo Pinar, A. Sampedro, M. Mareque & I. Oyagüez. (2023) Cost‐effectiveness analysis of dyevert™ Power XT in patients with chronic kidney disease undergoing percutaneous coronary intervention procedures in Spain. Catheterization and Cardiovascular Interventions 102:2, pages 233-240.
Crossref
Vivekanand Jha, Saeed M. G. Al-Ghamdi, Guisen Li, Mai-Szu Wu, Panagiotis Stafylas, Lise Retat, Joshua Card-Gowers, Salvatore Barone, Claudia Cabrera & Juan Jose Garcia Sanchez. (2023) Global Economic Burden Associated with Chronic Kidney Disease: A Pragmatic Review of Medical Costs for the Inside CKD Research Programme. Advances in Therapy.
Crossref
Phil McEwan, Oliver Darlington, Ryan Miller, John J.V. McMurray, David C. Wheeler, Hiddo J.L. Heerspink, Andrew Briggs, Klas Bergenheim & Juan Jose Garcia Sanchez. (2022) Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology 17:12, pages 1730-1741.
Crossref
Carlos Escobar, Cristóbal Morales, Margarita Capel, Susana Simón, Ferran Pérez-Alcántara & Elisenda Pomares. (2022) Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study. BMC Health Services Research 22:1.
Crossref
V. G. Kormilitsyna, V. G. Zaletaeva, S. O. Sharapchenko, R. Sh. Saidgareev, M. Yu. SinyakN. I. Gabrielyan. (2021) Comparison of clinical and cost effectiveness of accelerated study of sterility of intravascular catheters and drains. Medical alphabet:32, pages 44-47.
Crossref
Carlos Escobar, Beatriz Palacios, Unai Aranda, Margarita Capel, Antoni Sicras, Aram Sicras, Antonio Hormigo, Roberto Alcázar, Nicolás Manito & Manuel Botana. (2021) Costs and healthcare utilisation of patients with chronic kidney disease in Spain. BMC Health Services Research 21:1.
Crossref
E. I. Rumiantseva & M. V. Avxentyeva. (2021) An economic evaluation of pre-dialysis stage of chronic kidney disease. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology 14:3, pages 365-378.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.